Robert I Blum Cytokinetics Inc (CYTK) insider trading activity

Robert I Blum is President & CEO of CYTOKINETICS INC. Currently has a direct ownership of 363,108 shares of CYTK, which is worth approximately $21.4 Million. The most recent transaction as insider was on Jan 29, 2021, when has been sold 5,000 shares (Common Stock) at a price of $20.34 per share, resulting in proceeds of $101,700. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 363K

7.63% 3M change

8.64% 12M change

Total Value Held $21.4 Million

Robert I Blum Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 29 2021	SELL Open market or private sale	$101,700 $20.34 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Jan 29 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Jan 20 2021	SELL Open market or private sale	$102,050 $20.41 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Jan 20 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Jan 04 2021	SELL Open market or private sale	$101,150 $20.23 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Jan 04 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Dec 16 2020	SELL Open market or private sale	$102,550 $20.51 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Dec 16 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Dec 04 2020	SELL Open market or private sale	$86,800 $17.36 p/Share	5,000 Reduced 1.61%	305,589 Common Stock
Dec 04 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.58%	310,589 Common Stock
Nov 23 2020	SELL Open market or private sale	$78,650 $15.73 p/Share	5,000 Reduced 1.61%	304,868 Common Stock
Nov 23 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.59%	309,868 Common Stock
Nov 10 2020	SELL Open market or private sale	$82,500 $16.5 p/Share	5,000 Reduced 1.61%	304,868 Common Stock
Nov 10 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.59%	309,868 Common Stock
Oct 29 2020	SELL Open market or private sale	$75,750 $15.15 p/Share	5,000 Reduced 1.61%	304,868 Common Stock
Oct 29 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.59%	309,868 Common Stock
Oct 13 2020	SELL Open market or private sale	$79,700 $15.94 p/Share	5,000 Reduced 1.61%	304,868 Common Stock
Oct 13 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.59%	309,868 Common Stock
Oct 02 2020	SELL Open market or private sale	$112,650 $22.53 p/Share	5,000 Reduced 1.61%	304,868 Common Stock
Oct 02 2020	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 1.59%	309,868 Common Stock

Also insider at

GMDA

Gamida Cell Ltd. Healthcare

Director

RIB

Robert I Blum

President & CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYTK shares.

Notify only if

Value

Insider Trading

Get notified when an Cytokinetics Inc insider buys or sells CYTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to CYTOKINETICS INC

Track Activities on CYTK

Account